Literature DB >> 598422

Pharmacokinetic and concentration-effect relationships of clonidine in essential hypertension.

L M Wing, J L Reid, D S Davies, E A Neill, P Tippett, C T Dollery.   

Abstract

The effect of oral doses of 300 microgram of clonidine hydrochloride on blood pressure, sedation and saliva production in 5 essential hypertensives were qualitatively similar to the effects in normotensive subjects. Peak plasma clonidine concentration (1.34 +/- 0.28 ng/ml) and plasma half-life (10.0 +/- 0.8 h) were similar to normotensives. During chronic oral dosing there was no evidence of drug accumulation. Some tolerance to the sedative and salivary flow effects occurred but no tolerance to the hypotensive effect was observed. There was a linear relationship between reduction in saliva flow and plasma levels of clonidine. The hypotensive effect was also related to plasma level at low concentrations. At plasma levels greater than 1.5 ng/ml the hypotensive effect was diminished. This loss of effect at high plasma concentration may be related to the peripheral, post-synaptic alpha-adrenoceptor agonist action of the drug.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 598422     DOI: 10.1007/bf00561067

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  9 in total

1.  Clonidine overdose.

Authors:  S N Hunyor; K Bradstock; P J Somerville; N Lucas
Journal:  Br Med J       Date:  1975-10-04

2.  Clinical pharmacology and pharmacokinetics of clonidine.

Authors:  C T Dollery; D S Davies; G H Draffan; H J Dargie; C R Dean; J L Reid; R A Clare; S Murray
Journal:  Clin Pharmacol Ther       Date:  1976-01       Impact factor: 6.875

3.  Pharmacokinetics and concentration-effect relationships of intervenous and oral clonidine.

Authors:  D S Davies; A M Wing; J L Reid; D M Neill; P Tippett; C T Dollery
Journal:  Clin Pharmacol Ther       Date:  1977-05       Impact factor: 6.875

4.  The central hypotensive effect of clonidine. Studies in tetraplegic subjects.

Authors:  J L Reid; L M Wing; C J Mathias; H L Frankel; E Neill
Journal:  Clin Pharmacol Ther       Date:  1977-04       Impact factor: 6.875

5.  Intravenous clonidine in hypertensive patients.

Authors:  W J Mroczek; M Davidov; F A Finnerty
Journal:  Clin Pharmacol Ther       Date:  1973 Sep-Oct       Impact factor: 6.875

6.  [Blood circulation studies with 2-(2,6-dichlorphenylamino)-2-imidazoline hydrochloride].

Authors:  W Kobinger; A Walland
Journal:  Arzneimittelforschung       Date:  1967-03

7.  Some observations on the inhibition of salivation by St 155 [2-(2,6-dichlorophenylamine)-2-imidazoline hydrochloride, Catapres, Catapresan].

Authors:  M J Rand; M Rush; J Wilson
Journal:  Eur J Pharmacol       Date:  1969-01       Impact factor: 4.432

8.  Antihypertensive effect of clonidine.

Authors:  G Onesti; A B Schwartz; K E Kim; V Paz-Martinez; C Swartz
Journal:  Circ Res       Date:  1971-05       Impact factor: 17.367

9.  Localization of the hypotenisve effect of 2-(2-6-dichlorophenylamino)-2-imidazoline hydrochloride (St 155, Catapresan).

Authors:  H Schmitt; H Schmitt
Journal:  Eur J Pharmacol       Date:  1969-04       Impact factor: 4.432

  9 in total
  19 in total

1.  A comparison of the haemodynamic and behavioural effects of moxonidine and clonidine in normotensive subjects.

Authors:  G J Macphee; C A Howie; H L Elliott; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1992-03       Impact factor: 4.335

Review 2.  Antihypertensive therapy in the aged patient. Clinical pharmacokinetic considerations.

Authors:  R W Piepho; K J Fendler
Journal:  Drugs Aging       Date:  1991-05       Impact factor: 3.923

Review 3.  Is clonidine an effective smoking cessation therapy?

Authors:  S G Gourlay; N L Benowitz
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

4.  New aspects of the pharmacokinetics and pharmacodynamics of clonidine in man.

Authors:  D Arndts; J Doevendans; R Kirsten; B Heintz
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  Differences in psychic performance with guanfacine and clonidine in normotensive subjects.

Authors:  J Kugler; R Seus; R Krauskopf; H M Brecht; A Raschig
Journal:  Br J Clin Pharmacol       Date:  1980       Impact factor: 4.335

6.  The Fourth Lilly Prize Lecture, University of Aberdeen, September 1980. The clinical pharmacology of clonidine and related central antihypertensive agents.

Authors:  J L Reid
Journal:  Br J Clin Pharmacol       Date:  1981-09       Impact factor: 4.335

7.  Tissue pharmacokinetics of clonidine in rats.

Authors:  E L Conway; B Jarrott
Journal:  J Pharmacokinet Biopharm       Date:  1982-04

8.  Antihypertensive effects of lofexidine in patients with essential hypertension.

Authors:  T C Fagan; S S Bloomfield; T D Cowart; R H Corns-Hurwitz; R J Lipicky; E C Conradi; C Y Hsu; W J Grossman; G E Harmon; W J Degenhart; A W Sinkfield; T E Gaffney
Journal:  Br J Clin Pharmacol       Date:  1982-03       Impact factor: 4.335

9.  Clonidine kinetics in man--evidence for dose dependency and changed pharmacokinetics during chronic therapy.

Authors:  M Frisk-Holmberg; L Paalzow; P O Edlund
Journal:  Br J Clin Pharmacol       Date:  1981-11       Impact factor: 4.335

10.  Acute hypotensive action of clonidine after intravenous infusion in hypertensive emergencies.

Authors:  F Pérez-Acuña; P Monsalve; J Pérez; J Pérez; A Tremarias; A Sanabria; F Fragachán
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.